Targeting the aryl hydrocarbon receptor as a strategy to expand the therapeutic armamentarium in atopic dermatitis by Lawrence F. Eichenfield, Jonathan I. Silverberg, Adelaide A. Hebert, Mark Boguniewicz

Get full text

Abrocitinib monotherapy in Investigator’s Global Assessment nonresponders: improvement in signs and symptoms of atopic dermatitis and quality of life by Andrew Blauvelt, Mark Boguniewicz, Patrick M. Brunner, Paula C. Luna, Pinaki Biswas, Marco DiBonaventura, Saleem A. Farooqui, Ricardo Rojo, Michael C. Cameron

Get full text

Managing Childhood and Adolescent Atopic Dermatitis in Primary Care: A US Expert Group Consensus by Mark Boguniewicz, MD, Moise L. Levy, MD, Lawrence F. Eichenfield, MD, Christine T. Lauren, MD, MHA, Donald Y.M. Leung, MD, PhD, Lynda C. Schneider, MD, Elaine C. Siegfried, MD, Wynnis L. Tom, MD, Amy S. Paller, MD

Get full text

Rapid Itch Improvement and Skin Clearance with Upadacitinib Versus Placebo (Measure Up 1 and Measure Up 2) and Versus Dupilumab (Heads Up): Results from Three Phase 3 Clinical Tria... by Eric L. Simpson, Jonathan I. Silverberg, Vimal H. Prajapati, Kilian Eyerich, Norito Katoh, Mark Boguniewicz, Emma Guttman-Yassky, E. James Song, Wan-Ju Lee, Henrique D. Teixeira, Tianshuang Wu, Cristina Sancho Sanchez, Namita Vigna, Brian M. Calimlim, Marjolein de Bruin-Weller

Get full text